Last Updated : October 30, 2024
Details
FilesGeneric Name:
Nab-paclitaxel
Project Status:
Complete
Therapeutic Area:
Gastrointestinal cancer
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
PX0354-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
In combination with gemcitabine, for previously treated advanced (locally advanced unresectable or metastatic) pancreatic cancer
Recommendation Type:
Do not reimburse
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | January 02, 2024 |
|---|---|
| Call for patient/clinician input closed | February 26, 2024 |
| Call for industry input open | January 02, 2024 |
| Call for industry input closed | February 26, 2024 |
| Submission received | December 21, 2023 |
| Expert committee meeting (initial) | July 04, 2024 |
| Draft recommendation posted for stakeholder feedback | August 01, 2024 |
| End of feedback period | August 16, 2024 |
| Final recommendation posted | September 24, 2024 |
| Canada's Drug Agency review report(s) posted | August 19, 2024 |
Files
Last Updated : October 30, 2024